Is biote Corp. overvalued or undervalued?

As of 22 June 2022, the valuation grade for Biote Corp. has moved from does not qualify to risky, indicating a shift in perception towards the company's financial health. The company appears to be undervalued, particularly when considering its low P/E ratio of 5.23 compared to peers, alongside an EV to EBITDA ratio of 6.63 and a PEG ratio of 0.43, which suggests potential for growth relative to its price.
In comparison to its peers, Biote Corp. has a significantly lower P/E ratio than National HealthCare Corp., which stands at 15.83, and a comparable EV to EBITDA ratio to Brookdale Senior Living, Inc. at 3.19. Despite the company's recent struggles, including a year-to-date return of -35.11% compared to the S&P 500's 2.44%, the underlying metrics indicate that Biote Corp. may present a buying opportunity for investors seeking value in the biotech sector.